IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Serial No.: 10/058,835

Group Art Unit: 1614

Filed: January 30, 2002

Examiner: Unassigned

For:

METHODS FOR SUSTAINED RELEASE LOCAL

DELIVERY OF DRUGS FOR ABLATION OF UNWANTED TISSUE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

CITED MATERIALS

Applic	nt(s) hereby disclose the information listed in the attached form PTO-1449.							
	Copies of materials listed but not attached were cited in parent application Serial No; see 37 C.F.R. § 1.98(d).							
	Copies of materials listed but not attached were cited in an International Search Report dated; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed							
LANG	JAGE							
	All listed materials are in the English language; see 37 C.F.R. § 1.98.							
	Non-English language references:							
	☐ The reference(s): in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): , respectively.							
	☐ (An) English-language translation(s) of the references: is (are) provided.							
	☐ A commercial English-language abstract of reference(s) is (are) provided.							
	An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).							

FEES



No fee is required for this Information Disclosure Statement because:

This Information Disclosure Statement is being filed within three more of the filing date of a national application (other than a CPA) under § 1.53(discretely 1.53) within 3 months of the date of entry of the national stage under § 1.491 in application;

This Information Disclosure Statement is being filed before the mailing of a first action on the merits;

This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.

☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).

A fee is required for this Information Disclosure Statement:

This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).

This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.

CERTIFICATION

- Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

OLE COS.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$_____. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to a facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

John A. Sopp, Reg. No. 33,103

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: UMICH-11

Date: November 1, 2002

JAS:jph

K:\Umich\11\Information Disclosure Statement.dot

PTO/SB/08A (08-00)

MON 0 1 5005 Under the Paperwork Reduction Act of 1995(Sp. persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

140/058 835 Approved for use through 10/31/2002. OMB 0651-0031 OU.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of Application Number 10/058,835 Filing Date January 30, 2002 RICHARDSON ET AL First Named Inventor Group Art Unit 1614 Unassigned **Examiner Name** Attorney Docket Number UMICH 11

U.S. PATENT DOCUMENTS								
	T	U.S. Pa	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials *	Cite No. ¹	Number	Kind C		Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	 	_						
		 		· -				
	ļ							
<u>-</u>	-	-						
	 							
		 						
-	+							
								
						L	<u> </u>	

		•		FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Fore Office ³		ment ind Code ⁵ if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ₆
	001	WIPO	WO 02/060410	ii kilowii)	Univ. of Michigan	8/8/2002	riguies Appear	
	002	WIPO	WO 98/46211		Amgen Inc.	10/22/1998		
	003	FR	2762319		Pharma Biotech Societe Anonyme	10/23/1998		

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Please type a plus sign (+) inside this box	Please	type a	plus	sign	(+)	inside	this	box
---	--------	--------	------	------	-----	--------	------	-----

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1998 go persons are regorded to respond to a collection of information unless it contains a valid OMB control number

Complete if Kn wn

Substitute t	for form 1449A/PTO)	-da-	Complete if Kn wn		
INITOI	DRAATION	DIC	CLOCUPE	Application Number	10/058,835	
_	=	_	CLOSURE	Filing Date	January 30, 2002	
STATEMENT BY APPLICANT				First Named Inventor	RICHARDSON et al.	
				Group Art Unit	1614	
(use as many she	ets as	necessary)	Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	UMICH-11	

	,	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	004	M. IWATA et al., In vitro and in vivo release properties of brilliant blue and tumor necrosis factor-alpha (TNF-a) from poly(D,L-lactic-co-glycolic acid) multiphase microspheres, J. Microencapsulation, 1999, Vol. 16, No. 6, 777-792	
			_
		TON CONTRACTOR OF THE PARTY OF	5/2
		The state of the s	200
		O SO	
		- Carlotte and the carl	

Examiner	Date	
Signature	Considered	
	 	<u> </u>

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.